Global Parkinson’s disease Therapeutics Market: Industry Analysis and forecast (2019 to 2026): By Drug Class, Route of Administration Analysis, Route of Administration Analysis and Region

Global Parkinson’s disease Therapeutics Market: Industry Analysis and forecast (2019 to 2026): By Drug Class, Route of Administration Analysis, Route of Administration Analysis and Region

Market Scenario

Global Parkinson’s disease Therapeutics Market was valued US$ XX Bn in 2018 and is expected to reach US$ XX Bn by 2026, at CAGR of 11 % during forecast period of 2019 to 2026. Global Parkinson’s disease Therapeutics Marketj Parkinson's disease is a highly prevalent age-related neurodegenerative disorder, affecting millions of people worldwide and causing severe impact on their physical, psychological, as well as emotional health. It is largely prevalent among the geriatric population. Global Parkinson’s disease Therapeutics Market by key segmentation Oral route of administration, followed by intestinal infusion segment, dominates the global market. More than 80% of the drugs available for treatment of Parkinson's disease are in the form of tablet and capsule. Some of the drugs are orally disintegrated. Also, rise in adoption and demand for subcutaneous injections and promising pipeline products with subcutaneous route of administration for home management of Parkinson's disease are estimated to limit the growth of the oral route of administration segment by the end of 2026. Retail pharmacy followed by hospital pharmacy segment, dominates the market. Among distribution channels, the retail pharmacy segment is projected to hold largest share of global market hold the dominant share of the global Parkinson's disease therapeutics market during the forecast period and is likely to expand the global market. Easy availability of Parkinson's therapeutic drugs at retail pharmacies, low price of the drugs, and expansion of leading retail pharmaceutical chains across the globe are driving the growth of the segment. The online pharmacy segment is poised to grow at as significant CAGR during the forecast period. Global Parkinson’s disease Therapeutics Market by drivers and restraints Recent advances in Parkinson’s disease therapeutics such as combination therapies to prolong the action of continuous dopaminergic stimulation drugs, approval for neurostimulation devices and neuroprotective therapies to slow down prognosis of a disease, gene therapy, neural transplantation etc., are expected to bring rapid growth in global Parkinson’s disease therapeutics market over the forecast period. Aging population and prevalence of Parkinsonism across the world are the factors fueling demand for Parkinson’s disease therapeutics. However, expiry of patents for several drugs such as Rytary, Stalevo (2012), Azilect (2017), Comtan (exclusivity expired in 2013) would hinder the global Parkinson’s disease therapeutics Market in forecast period. Global Parkinson’s disease Therapeutics Market by regional analysis North America Held largest share in global Parkinson’s disease Therapeutics Market. According to Parkinson’s disease Foundation (PDF) approximately XX thousand Americans are diagnosed with Parkinson’s disease annually. Europe is expected to hold second highest share in the global market. Large number of key players focusing on research and developments activities to introduce technologically-advanced Parkinson’s disease Therapeutics with better designs drive the market in the region. The objective of the report is to present comprehensive analysis of Global Parkinson’s Disease Therapeutics Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers. The report also helps in understanding Global Parkinson’s Disease Therapeutics Market dynamics, structure by analyzing the market segments, and project the Global Parkinson’s Disease Therapeutics Market size. Clear representation of competitive analysis of key players by Parkinson’s Disease Therapeutics Type, price, financial position, product portfolio, growth strategies, and regional presence in the Global Parkinson’s Disease Therapeutics Market make the report investor’s guide.

Global Parkinson’s disease Therapeutics Market by Drug Class

• Levodopa Combination • Dopamine Agonists • Monoamine Oxidase B (Mao-B) Inhibitors • Anticholinergic Drugs • Catechol-O-Methyltransferase (COMT) Inhibitors

Global Parkinson’s disease Therapeutics Market by Route of Administration Analysis

• Oral • Transdermal • Subcutaneous • Intestinal Infusion

Global Parkinson’s disease Therapeutics Market by Distribution Channel Analysis

• Hospital Pharmacy • Retail Pharmacy • Online Sales

Global Parkinson’s disease Therapeutics Market by region

• Asia Pacific • North America • Europe • Latin America • Middle East Africa

Key players operating on Global Parkinson’s disease Therapeutics Market

• GlaxoSmithKline Plc., • Salix Pharmaceuticals, • map Laboratories, Inc., • Teva Pharmaceutical Industries Ltd., • Novartis AG, Orion Corporation, • Mylan N.V. • Abbvie, Inc. • Biogen, Inc. • Boehringer Ingelheim GmbH • F. Hoffman-La Roche • GlaxoSmithKline Plc. • H. Lundbeck A/S • Impax Labs, Inc. • Newron Pharmaceuticals SpA • Novartis AG • Orion Corporation • UCB S.A.  

Table of Contents

Global Parkinson’s disease Therapeutics Market 1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Parkinson’s disease Therapeutics Market Size, by Market Value (US$ Bn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Global Parkinson’s disease Therapeutics Market Analysis and Forecast 6.1. Global Parkinson’s disease Therapeutics Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global Parkinson’s disease Therapeutics Market Analysis and Forecast, by Drug class 7.1. Introduction and Definition 7.2. Key Findings 7.3. Global Parkinson’s disease Therapeutics Market Value Share Analysis, by Drug class 7.4. Global Parkinson’s disease Therapeutics Market Size (US$ Bn) Forecast, by Drug class 7.5. Global Parkinson’s disease Therapeutics Market Analysis, by Drug class 7.6. Global Parkinson’s disease Therapeutics Market Attractiveness Analysis, by Drug class 8. Global Parkinson’s disease Therapeutics Market Analysis and Forecast, by Administration route 8.1. Introduction and Definition 8.2. Key Findings 8.3. Global Parkinson’s disease Therapeutics Market Value Share Analysis, by Administration route 8.4. Global Parkinson’s disease Therapeutics Market Size (US$ Bn) Forecast, by Administration route 8.5. Global Parkinson’s disease Therapeutics Market Analysis, by Administration route 8.6. Global Parkinson’s disease Therapeutics Market Attractiveness Analysis, by Administration route 9. Global Parkinson’s disease Therapeutics Market Analysis and Forecast, by Distribution channel 9.1. Introduction and Definition 9.2. Key Findings 9.3. Global Parkinson’s disease Therapeutics Market Value Share Analysis, by Distribution channel 9.4. Global Parkinson’s disease Therapeutics Market Size (US$ Bn) Forecast, by Distribution channel 9.5. Global Parkinson’s disease Therapeutics Market Analysis, by Distribution channel 9.6. Global Parkinson’s disease Therapeutics Market Attractiveness Analysis, by Distribution channel 10. Global Parkinson’s disease Therapeutics Market Analysis, by Region 10.1. Global Parkinson’s disease Therapeutics Market Value Share Analysis, by Region 10.2. Global Parkinson’s disease Therapeutics Market Size (US$ Bn) Forecast, by Region 10.3. Global Parkinson’s disease Therapeutics Market Attractiveness Analysis, by Region 11. North America Parkinson’s disease Therapeutics Market Analysis 11.1. Key Findings 11.2. North America Parkinson’s disease Therapeutics Market Overview 11.3. North America Parkinson’s disease Therapeutics Market Value Share Analysis, by Drug class 11.4. North America Parkinson’s disease Therapeutics Market Forecast, by Drug class 11.4.1. Levodopa Combination 11.4.2. Dopamine Agonists 11.4.3. Monoamine Oxidase B (Mao-B) Inhibitors 11.4.4. Anticholinergic Drugs 11.4.5. Catechol-O-Methyltransferase (COMT) Inhibitors 11.5. North America Parkinson’s disease Therapeutics Market Value Share Analysis, by Administration route 11.6. North America Parkinson’s disease Therapeutics Market Forecast, by Administration route 11.6.1. Oral 11.6.2. Transdermal 11.6.3. Subcutaneous 11.6.4. Intestinal Infusion 11.7. North America Parkinson’s disease Therapeutics Market Value Share Analysis, by Distribution channel 11.8. North America Parkinson’s disease Therapeutics Market Forecast, by Distribution channel 11.8.1. Hospital Pharmacy 11.8.2. Retail Pharmacy 11.8.3. Online Sales 11.9. North America Parkinson’s disease Therapeutics Market Value Share Analysis, by Country 11.10. North America Parkinson’s disease Therapeutics Market Forecast, by Country 11.10.1. U.S. 11.10.2. Canada 11.11. North America Parkinson’s disease Therapeutics Market Analysis, by Country 11.12. U.S. Parkinson’s disease Therapeutics Market Forecast, by Drug class 11.12.1. Levodopa Combination 11.12.2. Dopamine Agonists 11.12.3. Monoamine Oxidase B (Mao-B) Inhibitors 11.12.4. Anticholinergic Drugs 11.12.5. Catechol-O-Methyltransferase (COMT) Inhibitors 11.13. U.S. Parkinson’s disease Therapeutics Market Forecast, by Administration route 11.13.1. Oral 11.13.2. Transdermal 11.13.3. Subcutaneous 11.13.4. Intestinal Infusion 11.14. U.S. Parkinson’s disease Therapeutics Market Forecast, by Distribution channel 11.14.1. Hospital Pharmacy 11.14.2. Retail Pharmacy 11.14.3. Online Sales 11.15. Canada Parkinson’s disease Therapeutics Market Forecast, by Drug class 11.15.1. Levodopa Combination 11.15.2. Dopamine Agonists 11.15.3. Monoamine Oxidase B (Mao-B) Inhibitors 11.15.4. Anticholinergic Drugs 11.15.5. Catechol-O-Methyltransferase (COMT) Inhibitors 11.16. Steel Canada Parkinson’s disease Therapeutics Market Forecast, by Administration route 11.16.1. Oral 11.16.2. Transdermal 11.16.3. Subcutaneous 11.16.4. Intestinal Infusion 11.17. Canada Parkinson’s disease Therapeutics Market Forecast, by Distribution channel 11.17.1. Hospital Pharmacy 11.17.2. Retail Pharmacy 11.17.3. Online Sales 11.18. North America Parkinson’s disease Therapeutics Market Attractiveness Analysis 11.18.1. By Drug class 11.18.2. By Administration route 11.18.3. By Distribution channel 11.19. PEST Analysis 11.20. Key Trends 11.21. Key Developments 12. Europe Parkinson’s disease Therapeutics Market Analysis 12.1. Key Findings 12.2. Europe Parkinson’s disease Therapeutics Market Overview 12.3. Europe Parkinson’s disease Therapeutics Market Value Share Analysis, by Drug class 12.4. Europe Parkinson’s disease Therapeutics Market Forecast, by Drug class 12.4.1. Levodopa Combination 12.4.2. Dopamine Agonists 12.4.3. Monoamine Oxidase B (Mao-B) Inhibitors 12.4.4. Anticholinergic Drugs 12.4.5. Catechol-O-Methyltransferase (COMT) Inhibitors 12.5. Europe Parkinson’s disease Therapeutics Market Value Share Analysis, by Administration route 12.6. Europe Parkinson’s disease Therapeutics Market Forecast, by Administration route 12.6.1. Oral 12.6.2. Transdermal 12.6.3. Subcutaneous 12.6.4. Intestinal Infusion 12.7. Europe Parkinson’s disease Therapeutics Market Value Share Analysis, by Distribution channel 12.8. Europe Parkinson’s disease Therapeutics Market Forecast, by Distribution channel 12.8.1. Hospital Pharmacy 12.8.2. Retail Pharmacy 12.8.3. Online Sales 12.9. Europe Parkinson’s disease Therapeutics Market Value Share Analysis, by Country 12.10. Europe Parkinson’s disease Therapeutics Market Forecast, by Country 12.10.1. Germany 12.10.2. U.K. 12.10.3. France 12.10.4. Italy 12.10.5. Spain 12.10.6. Rest of Europe 12.11. Europe Parkinson’s disease Therapeutics Market Analysis, by Country 12.12. Germany Parkinson’s disease Therapeutics Market Forecast, by Drug class 12.12.1. Levodopa Combination 12.12.2. Dopamine Agonists 12.12.3. Monoamine Oxidase B (Mao-B) Inhibitors 12.12.4. Anticholinergic Drugs 12.12.5. Catechol-O-Methyltransferase (COMT) Inhibitors 12.13. Germany Parkinson’s disease Therapeutics Market Forecast, by Administration route 12.13.1. Oral 12.13.2. Transdermal 12.13.3. Subcutaneous 12.13.4. Intestinal Infusion 12.14. Germany Parkinson’s disease Therapeutics Market Forecast, by Distribution channel 12.14.1. Hospital Pharmacy 12.14.2. Retail Pharmacy 12.14.3. Online Sales 12.15. U.K. Parkinson’s disease Therapeutics Market Forecast, by Drug class 12.15.1. Levodopa Combination 12.15.2. Dopamine Agonists 12.15.3. Monoamine Oxidase B (Mao-B) Inhibitors 12.15.4. Anticholinergic Drugs 12.15.5. Catechol-O-Methyltransferase (COMT) Inhibitors 12.16. U.K. Parkinson’s disease Therapeutics Market Forecast, by Administration route 12.16.1. Oral 12.16.2. Transdermal 12.16.3. Subcutaneous 12.16.4. Intestinal Infusion 12.17. U.K. Parkinson’s disease Therapeutics Market Forecast, by Distribution channel 12.17.1. Hospital Pharmacy 12.17.2. Retail Pharmacy 12.17.3. Online Sales 12.18. France Parkinson’s disease Therapeutics Market Forecast, by Drug class 12.18.1. Levodopa Combination 12.18.2. Dopamine Agonists 12.18.3. Monoamine Oxidase B (Mao-B) Inhibitors 12.18.4. Anticholinergic Drugs 12.18.5. Catechol-O-Methyltransferase (COMT) Inhibitors 12.19. France Parkinson’s disease Therapeutics Market Forecast, by Administration route 12.19.1. Oral 12.19.2. Transdermal 12.19.3. Subcutaneous 12.19.4. Intestinal Infusion 12.20. France Parkinson’s disease Therapeutics Market Forecast, by Distribution channel 12.20.1. Hospital Pharmacy 12.20.2. Retail Pharmacy 12.20.3. Online Sales 12.21. Italy Parkinson’s disease Therapeutics Market Forecast, by Drug class 12.21.1. Levodopa Combination 12.21.2. Dopamine Agonists 12.21.3. Monoamine Oxidase B (Mao-B) Inhibitors 12.21.4. Anticholinergic Drugs 12.21.5. Catechol-O-Methyltransferase (COMT) Inhibitors 12.22. Italy Parkinson’s disease Therapeutics Market Forecast, by Administration route 12.22.1. Oral 12.22.2. Transdermal 12.22.3. Subcutaneous 12.22.4. Intestinal Infusion 12.23. Italy Parkinson’s disease Therapeutics Market Forecast, by Distribution channel 12.23.1. Hospital Pharmacy 12.23.2. Retail Pharmacy 12.23.3. Online Sales 12.24. Spain Parkinson’s disease Therapeutics Market Forecast, by Drug class 12.24.1. Levodopa Combination 12.24.2. Dopamine Agonists 12.24.3. Monoamine Oxidase B (Mao-B) Inhibitors 12.24.4. Anticholinergic Drugs 12.24.5. Catechol-O-Methyltransferase (COMT) Inhibitors 12.25. Spain Parkinson’s disease Therapeutics Market Forecast, by Administration route 12.25.1. Oral 12.25.2. Transdermal 12.25.3. Subcutaneous 12.25.4. Intestinal Infusion 12.26. Spain Parkinson’s disease Therapeutics Market Forecast, by Distribution channel 12.26.1. Hospital Pharmacy 12.26.2. Retail Pharmacy 12.26.3. Online Sales 12.27. Rest of Europe Parkinson’s disease Therapeutics Market Forecast, by Drug class 12.27.1. Levodopa Combination 12.27.2. Dopamine Agonists 12.27.3. Monoamine Oxidase B (Mao-B) Inhibitors 12.27.4. Anticholinergic Drugs 12.27.5. Catechol-O-Methyltransferase (COMT) Inhibitors 12.28. Rest of Europe Parkinson’s disease Therapeutics Market Forecast, by Administration route 12.28.1. Oral 12.28.2. Transdermal 12.28.3. Subcutaneous 12.28.4. Intestinal Infusion 12.29. Rest Of Europe Parkinson’s disease Therapeutics Market Forecast, by Distribution channel 12.29.1. Hospital Pharmacy 12.29.2. Retail Pharmacy 12.29.3. Online Sales 12.30. Europe Parkinson’s disease Therapeutics Market Attractiveness Analysis 12.30.1. By Drug class 12.30.2. By Administration route 12.30.3. By Distribution channel 12.31. PEST Analysis 12.32. Key Trends 12.33. Key Developments 13. Asia Pacific Parkinson’s disease Therapeutics Market Analysis 13.1. Key Findings 13.2. Asia Pacific Parkinson’s disease Therapeutics Market Overview 13.3. Asia Pacific Parkinson’s disease Therapeutics Market Value Share Analysis, by Drug class 13.4. Asia Pacific Parkinson’s disease Therapeutics Market Forecast, by Drug class 13.4.1. Levodopa Combination 13.4.2. Dopamine Agonists 13.4.3. Monoamine Oxidase B (Mao-B) Inhibitors 13.4.4. Anticholinergic Drugs 13.4.5. Catechol-O-Methyltransferase (COMT) Inhibitors 13.5. Asia Pacific Parkinson’s disease Therapeutics Market Value Share Analysis, by Administration route 13.6. Asia Pacific Parkinson’s disease Therapeutics Market Forecast, by Administration route 13.6.1. Oral 13.6.2. Transdermal 13.6.3. Subcutaneous 13.6.4. Intestinal Infusion 13.7. Asia Pacific Parkinson’s disease Therapeutics Market Value Share Analysis, by Distribution channel 13.8. Asia Pacific Parkinson’s disease Therapeutics Market Forecast, by Distribution channel 13.8.1. Hospital Pharmacy 13.8.2. Retail Pharmacy 13.8.3. Online Sales 13.9. Asia Pacific Parkinson’s disease Therapeutics Market Value Share Analysis, by Country 13.10. Asia Pacific Parkinson’s disease Therapeutics Market Forecast, by Country 13.10.1. China 13.10.2. India 13.10.3. Japan 13.10.4. ASEAN 13.10.5. Rest of Asia Pacific 13.11. Asia Pacific Parkinson’s disease Therapeutics Market Analysis, by Country 13.12. China Parkinson’s disease Therapeutics Market Forecast, by Drug class 13.12.1. Levodopa Combination 13.12.2. Dopamine Agonists 13.12.3. Monoamine Oxidase B (Mao-B) Inhibitors 13.12.4. Anticholinergic Drugs 13.12.5. Catechol-O-Methyltransferase (COMT) Inhibitors 13.13. China Parkinson’s disease Therapeutics Market Forecast, by Administration route 13.13.1. Oral 13.13.2. Transdermal 13.13.3. Subcutaneous 13.13.4. Intestinal Infusion 13.14. China Parkinson’s disease Therapeutics Market Forecast, by Distribution channel 13.14.1. Hospital Pharmacy 13.14.2. Retail Pharmacy 13.14.3. Online Sales 13.15. India Parkinson’s disease Therapeutics Market Forecast, by Drug class 13.15.1. Levodopa Combination 13.15.2. Dopamine Agonists 13.15.3. Monoamine Oxidase B (Mao-B) Inhibitors 13.15.4. Anticholinergic Drugs 13.15.5. Catechol-O-Methyltransferase (COMT) Inhibitors 13.16. India Parkinson’s disease Therapeutics Market Forecast, by Administration route 13.16.1. Oral 13.16.2. Transdermal 13.16.3. Subcutaneous 13.16.4. Intestinal Infusion 13.17. India Parkinson’s disease Therapeutics Market Forecast, by Distribution channel 13.17.1. Hospital Pharmacy 13.17.2. Retail Pharmacy 13.17.3. Online Sales 13.18. Japan Parkinson’s disease Therapeutics Market Forecast, by Drug class 13.18.1. Levodopa Combination 13.18.2. Dopamine Agonists 13.18.3. Monoamine Oxidase B (Mao-B) Inhibitors 13.18.4. Anticholinergic Drugs 13.18.5. Catechol-O-Methyltransferase (COMT) Inhibitors 13.19. Japan Parkinson’s disease Therapeutics Market Forecast, by Administration route 13.19.1. Oral 13.19.2. Transdermal 13.19.3. Subcutaneous 13.19.4. Intestinal Infusion 13.20. Japan Parkinson’s disease Therapeutics Market Forecast, by Distribution channel 13.20.1. Hospital Pharmacy 13.20.2. Retail Pharmacy 13.20.3. Online Sales 13.21. ASEAN Parkinson’s disease Therapeutics Market Forecast, by Drug class 13.21.1. Levodopa Combination 13.21.2. Dopamine Agonists 13.21.3. Monoamine Oxidase B (Mao-B) Inhibitors 13.21.4. Anticholinergic Drugs 13.21.5. Catechol-O-Methyltransferase (COMT) Inhibitors 13.22. ASEAN Parkinson’s disease Therapeutics Market Forecast, by Administration route 13.22.1. Oral 13.22.2. Transdermal 13.22.3. Subcutaneous 13.22.4. Intestinal Infusion 13.23. ASEAN Parkinson’s disease Therapeutics Market Forecast, by Distribution channel 13.23.1. Hospital Pharmacy 13.23.2. Retail Pharmacy 13.23.3. Online Sales 13.24. Rest of Asia Pacific Parkinson’s disease Therapeutics Market Forecast, by Drug class 13.24.1. Levodopa Combination 13.24.2. Dopamine Agonists 13.24.3. Monoamine Oxidase B (Mao-B) Inhibitors 13.24.4. Anticholinergic Drugs 13.24.5. Catechol-O-Methyltransferase (COMT) Inhibitors 13.25. Rest of Asia Pacific Parkinson’s disease Therapeutics Market Forecast, by Administration route 13.25.1. Oral 13.25.2. Transdermal 13.25.3. Subcutaneous 13.25.4. Intestinal Infusion 13.26. Rest of Asia Pacific Parkinson’s disease Therapeutics Market Forecast, by Distribution channel 13.26.1. Hospital Pharmacy 13.26.2. Retail Pharmacy 13.26.3. Online Sales 13.27. Asia Pacific Parkinson’s disease Therapeutics Market Attractiveness Analysis 13.27.1. By Drug class 13.27.2. By Administration route 13.27.3. By Distribution channel 13.28. PEST Analysis 13.29. Key Trends 13.30. Key Developments 14. Middle East & Africa Parkinson’s disease Therapeutics Market Analysis 14.1. Key Findings 14.2. Middle East & Africa Parkinson’s disease Therapeutics Market Overview 14.3. Middle East & Africa Parkinson’s disease Therapeutics Market Value Share Analysis, by Drug class 14.4. Middle East & Africa Parkinson’s disease Therapeutics Market Forecast, by Drug class 14.4.1. Levodopa Combination 14.4.2. Dopamine Agonists 14.4.3. Monoamine Oxidase B (Mao-B) Inhibitors 14.4.4. Anticholinergic Drugs 14.4.5. Catechol-O-Methyltransferase (COMT) Inhibitors 14.5. Middle East & Africa Parkinson’s disease Therapeutics Market Value Share Analysis, by Administration route 14.6. Middle East & Africa Parkinson’s disease Therapeutics Market Forecast, by Administration route 14.6.1. Oral 14.6.2. Transdermal 14.6.3. Subcutaneous 14.6.4. Intestinal Infusion 14.7. Middle East & Africa Parkinson’s disease Therapeutics Market Value Share Analysis, by Distribution channel 14.8. Middle East & Africa Parkinson’s disease Therapeutics Market Forecast, by Distribution channel 14.8.1. Hospital Pharmacy 14.8.2. Retail Pharmacy 14.8.3. Online Sales 14.9. Middle East & Africa Parkinson’s disease Therapeutics Market Value Share Analysis, by Country 14.10. Middle East & Africa Parkinson’s disease Therapeutics Market Forecast, by Country 14.10.1. GCC 14.10.2. South Africa 14.10.3. Rest of Middle East & Africa 14.11. Middle East & Africa Parkinson’s disease Therapeutics Market Analysis, by Country 14.12. GCC Parkinson’s disease Therapeutics Market Forecast, by Drug class 14.12.1. Levodopa Combination 14.12.2. Dopamine Agonists 14.12.3. Monoamine Oxidase B (Mao-B) Inhibitors 14.12.4. Anticholinergic Drugs 14.12.5. Catechol-O-Methyltransferase (COMT) Inhibitors 14.13. GCC Parkinson’s disease Therapeutics Market Forecast, by Administration route 14.13.1. Oral 14.13.2. Transdermal 14.13.3. Subcutaneous 14.13.4. Intestinal Infusion 14.14. GCC Parkinson’s disease Therapeutics Market Forecast, by Distribution channel 14.14.1. Hospital Pharmacy 14.14.2. Retail Pharmacy 14.14.3. Online Sales 14.15. South Africa Parkinson’s disease Therapeutics Market Forecast, by Drug class 14.15.1. Levodopa Combination 14.15.2. Dopamine Agonists 14.15.3. Monoamine Oxidase B (Mao-B) Inhibitors 14.15.4. Anticholinergic Drugs 14.15.5. Catechol-O-Methyltransferase (COMT) Inhibitors 14.16. South Africa Parkinson’s disease Therapeutics Market Forecast, by Administration route 14.16.1. Oral 14.16.2. Transdermal 14.16.3. Subcutaneous 14.16.4. Intestinal Infusion 14.17. South Africa Parkinson’s disease Therapeutics Market Forecast, by Distribution channel 14.17.1. Hospital Pharmacy 14.17.2. Retail Pharmacy 14.17.3. Online Sales 14.18. Rest of Middle East & Africa Parkinson’s disease Therapeutics Market Forecast, by Drug class 14.18.1. Levodopa Combination 14.18.2. Dopamine Agonists 14.18.3. Monoamine Oxidase B (Mao-B) Inhibitors 14.18.4. Anticholinergic Drugs 14.18.5. Catechol-O-Methyltransferase (COMT) Inhibitors 14.19. Rest of Middle East & Africa Parkinson’s disease Therapeutics Market Forecast, by Administration route 14.19.1. Oral 14.19.2. Transdermal 14.19.3. Subcutaneous 14.19.4. Intestinal Infusion 14.20. Rest of Middle East & Africa Parkinson’s disease Therapeutics Market Forecast, by Distribution channel 14.20.1. Hospital Pharmacy 14.20.2. Retail Pharmacy 14.20.3. Online Sales 14.21. Middle East & Africa Parkinson’s disease Therapeutics Market Attractiveness Analysis 14.21.1. By Drug class 14.21.2. By Administration route 14.21.3. By Distribution channel 14.22. PEST Analysis 14.23. Key Trends 14.24. Key Developments 15. South America Parkinson’s disease Therapeutics Market Analysis 15.1. Key Findings 15.2. South America Parkinson’s disease Therapeutics Market Overview 15.3. South America Parkinson’s disease Therapeutics Market Value Share Analysis, by Drug class 15.4. South America Parkinson’s disease Therapeutics Market Forecast, by Drug class 15.4.1. Levodopa Combination 15.4.2. Dopamine Agonists 15.4.3. Monoamine Oxidase B (Mao-B) Inhibitors 15.4.4. Anticholinergic Drugs 15.4.5. Catechol-O-Methyltransferase (COMT) Inhibitors 15.5. South America Parkinson’s disease Therapeutics Market Value Share Analysis, by Administration route 15.6. South America Parkinson’s disease Therapeutics Market Forecast, by Administration route 15.6.1. On-Premises 15.6.2. Cloud 15.7. South America Parkinson’s disease Therapeutics Market Value Share Analysis, by Distribution channel 15.8. South America Parkinson’s disease Therapeutics Market Forecast, by Distribution channel 15.8.1. Hospital Pharmacy 15.8.2. Retail Pharmacy 15.8.3. Online Sales 15.9. South America Parkinson’s disease Therapeutics Market Value Share Analysis, by Country 15.10. South America Parkinson’s disease Therapeutics Market Forecast, by Country 15.10.1. Brazil 15.10.2. Mexico 15.10.3. Rest of South America 15.11. South America Parkinson’s disease Therapeutics Market Analysis, by Country 15.12. Brazil Parkinson’s disease Therapeutics Market Forecast, by Drug class 15.12.1. Levodopa Combination 15.12.2. Dopamine Agonists 15.12.3. Monoamine Oxidase B (Mao-B) Inhibitors 15.12.4. Anticholinergic Drugs 15.12.5. Catechol-O-Methyltransferase (COMT) Inhibitors 15.13. Brazil Parkinson’s disease Therapeutics Market Forecast, by Administration route 15.13.1. Oral 15.13.2. Transdermal 15.13.3. Subcutaneous 15.13.4. Intestinal Infusion 15.14. Brazil Parkinson’s disease Therapeutics Market Forecast, by Distribution channel 15.14.1. Hospital Pharmacy 15.14.2. Retail Pharmacy 15.14.3. Online Sales 15.15. Mexico Parkinson’s disease Therapeutics Market Forecast, by Drug class 15.15.1. Levodopa Combination 15.15.2. Dopamine Agonists 15.15.3. Monoamine Oxidase B (Mao-B) Inhibitors 15.15.4. Anticholinergic Drugs 15.15.5. Catechol-O-Methyl transferase (COMT) Inhibitors 15.16. Mexico Parkinson’s disease Therapeutics Market Forecast, by Administration route 15.16.1. Oral 15.16.2. Transdermal 15.16.3. Subcutaneous 15.16.4. Intestinal Infusion 15.17. Mexico Parkinson’s disease Therapeutics Market Forecast, by Distribution channel 15.17.1. Hospital Pharmacy 15.17.2. Retail Pharmacy 15.17.3. Online Sales 15.18. Rest of South America Parkinson’s disease Therapeutics Market Forecast, by Drug class 15.18.1. Levodopa Combination 15.18.2. Dopamine Agonists 15.18.3. Monoamine Oxidase B (Mao-B) Inhibitors 15.18.4. Anticholinergic Drugs 15.18.5. Catechol-O-Methyltransferase (COMT) Inhibitors 15.19. Rest of South America Parkinson’s disease Therapeutics Market Forecast, by Administration route 15.19.1. Oral 15.19.2. Transdermal 15.19.3. Subcutaneous 15.19.4. Intestinal Infusion 15.20. Rest of South America Parkinson’s disease Therapeutics Market Forecast, by Distribution channel 15.20.1. Hospital Pharmacy 15.20.2. Retail Pharmacy 15.20.3. Online Sales 15.21. South America Parkinson’s disease Therapeutics Market Attractiveness Analysis 15.21.1. By Drug class 15.21.2. By Administration route 15.21.3. By Distribution channel 15.22. PEST Analysis 15.23. Key Trends 15.24. Key Developments 16. Company Profiles 16.1. Market Share Analysis, by Company 16.2. Competition Matrix 16.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment 16.2.2. New Product Launches and Product Enhancements 16.2.3. Market Consolidation 16.2.3.1. M&A by Regions, Investment and Applications 16.2.3.2. M&A Key Players, Forward Integration and Backward Integration 16.3. Company Profiles: Key Players 16.3.1. GlaxoSmithKline Plc., 16.3.1.1. Company Overview 16.3.1.2. Financial Overview 16.3.1.3. Portfolio 16.3.1.4. Business Strategy 16.3.1.5. Recent Developments 16.3.1.6. Development Footprint 16.3.2. Salix Pharmaceuticals, 16.3.3. mpax Laboratories, Inc., 16.3.4. Teva Pharmaceutical Industries Ltd., 16.3.5. Novartis AG, Orion Corporation, 16.3.6. Mylan N.V. 16.3.7. Abbvie, Inc. 16.3.8. Biogen, Inc. 16.3.9. Boehringer Ingelheim GmbH 16.3.10. F. Hoffman-La Roche 16.3.11. GlaxoSmithKline Plc. 16.3.12. H. Lundbeck A/S 16.3.13. Impax Labs, Inc. 16.3.14. Newron Pharmaceuticals SpA 16.3.15. Novartis AG 16.3.16. Orion Corporation 16.3.17. UCB S.A. 17. Primary Key Insights

About This Report

Report ID36272
Published DateNov 2019
Contact Us
Call Now